Zealand Pharma Valuation

Is 22Z undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 22Z when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 22Z (€105) is trading above our estimate of fair value (€31.43)

Significantly Below Fair Value: 22Z is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 22Z?

Key metric: As 22Z barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 22Z. This is calculated by dividing 22Z's market cap by their current book value.
What is 22Z's PB Ratio?
PB Ratio6x
BookDKK 8.88b
Market CapDKK 53.44b

Price to Book Ratio vs Peers

How does 22Z's PB Ratio compare to its peers?

The above table shows the PB ratio for 22Z vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
BIO3 Biotest
2x29.3%€1.3b
FYB Formycon
1.6x30.6%€900.5m
HPHA Heidelberg Pharma
3.1x-33.0%€110.0m
2INV 2invest
1.1xn/a€66.7m
22Z Zealand Pharma
6x47.3%€53.4b

Price-To-Book vs Peers: 22Z is expensive based on its Price-To-Book Ratio (6x) compared to the peer average (1.9x).


Price to Book Ratio vs Industry

How does 22Z's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
22Z 6.0xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 22Z is expensive based on its Price-To-Book Ratio (6x) compared to the European Biotechs industry average (2.4x).


Price to Book Ratio vs Fair Ratio

What is 22Z's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

22Z PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 22Z's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 22Z forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€105.00
€136.50
+30.0%
9.9%€147.51€109.29n/a12
Dec ’25€96.95
€136.06
+40.3%
10.4%€147.45€109.25n/a11
Nov ’25€111.80
€135.08
+20.8%
11.7%€148.23€107.22n/a9
Oct ’25€109.70
€136.99
+24.9%
10.3%€148.21€107.20n/a7
Sep ’25€119.40
€136.08
+14.0%
10.0%€148.26€107.24n/a7
Aug ’25€121.50
€132.64
+9.2%
9.6%€147.40€107.20n/a7
Jul ’25€121.60
€123.08
+1.2%
12.2%€147.49€107.26n/a6
Jun ’25€85.40
€105.29
+23.3%
8.9%€112.58€83.77n/a7
May ’25€84.50
€104.84
+24.1%
10.0%€112.62€80.44n/a7
Apr ’25€91.45
€101.13
+10.6%
14.4%€112.62€76.42n/a7
Mar ’25€88.25
€80.32
-9.0%
26.1%€107.33€51.25n/a6
Feb ’25€62.45
€56.76
-9.1%
11.2%€65.03€47.60n/a6
Jan ’25€50.50
€50.83
+0.6%
11.7%€57.67€39.56n/a6
Dec ’24€44.40
€49.02
+10.4%
9.3%€53.67€39.58€96.956
Nov ’24€39.04
€46.12
+18.1%
9.3%€50.97€39.57€111.806
Oct ’24€39.64
€46.12
+16.3%
9.3%€50.97€39.57€109.706
Sep ’24€34.34
€42.19
+22.9%
12.5%€50.98€36.22€119.406
Aug ’24€31.16
€39.63
+27.2%
11.4%€45.65€31.55€121.506
Jul ’24€31.36
€39.63
+26.4%
11.4%€45.65€31.55€121.606
Jun ’24€35.48
€39.63
+11.7%
11.4%€45.65€31.55€85.406
May ’24€29.84
€39.17
+31.3%
11.3%€45.63€31.54€84.506
Apr ’24€30.70
€39.48
+28.6%
11.3%€44.69€31.54€91.455
Mar ’24€29.72
€34.58
+16.3%
5.3%€36.95€31.57€88.256
Feb ’24€28.20
€33.84
+20.0%
5.9%€36.97€31.46€62.456
Jan ’24€26.70
€32.45
+21.5%
8.9%€36.95€27.55€50.506
Dec ’23€26.86
€31.69
+18.0%
11.2%€36.95€26.88€44.406

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 01:34
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zealand Pharma A/S is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kerry HolfordBerenberg
Laura HindleyBerenberg
Charlie HaywoodBofA Global Research